Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026)

Damora Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 10975.56% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 10975.56% YoY), and the FY2025 full-year result was $81000.0, up 88.37% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $5.0 million, up from $81000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $5.0 million in Q1 2026, with the low at $43000.0 in Q4 2024.
• Historically, Other Non-Current Liabilities has averaged $875166.7 across 3 years, with a median of $49000.0 in 2025.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities jumped 88.37% — and 2026, when it surged 10975.56%.
• Damora Therapeutics' Other Non-Current Liabilities stood at $43000.0 in 2024, then jumped by 88.37% to $81000.0 in 2025, then surged by 6053.09% to $5.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.0 million (Q1 2026), $81000.0 (Q4 2025), and $49000.0 (Q3 2025), per Business Quant data.